Program ACTIVE II: Behavioral Depression Treatment for Type 2 Diabetes
NCT ID: NCT03371940
Last Updated: 2024-05-28
Study Results
Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.
View full resultsBasic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
140 participants
INTERVENTIONAL
2012-01-01
2017-07-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Effective Care Management of Depressed Diabetes Patients (The Positive Steps Study)
NCT01106885
Depression and Diabetes Control Trial
NCT02675257
Identifying the Effect and Working Mechanisms of MyPlan 2.0 in Adults With Type 2 Diabetes
NCT03291171
Evaluation of a Stepped Care Approach to Manage Depression in Diabetes
NCT01812291
Reducing Clinical Inertia in Diabetes Care
NCT00272402
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Two primary study aims will be addressed by Program ACTIVE II: 1) to compare changes in glycemic control across intervention groups to UC at POST and 6- and 12-month follow-up assessments; and 2) to compare changes in MDD outcomes across intervention groups (i.e. CBT, EXER, CBT+EXER) to usual care (UC) following intervention (POST) and 6- and 12-month follow-up assessments.
The primary hypotheses are:
1. Diabetes Outcomes. Based on the investigators' pilot data, mean glycemic control (as measured by HbA1c) is expected to improve .4% in participants in the EXER and CBT+EXER treatment conditions at POST compared to baseline \[de Groot et al 2009\]. Participants assigned to the CBT+EXER treatment are expected to show the greatest improvement in HbA1c followed by those in the EXER group in comparison to the CBT group. No improvement is expected among those assigned to the UC condition.
2. Depression. Participants in the CBT, EXER and CBT+EXER conditions will show clinically significant improvements in BDI and diagnosis of MDD at POST and 6- and 12-month assessments with the greatest improvements expected among those in CBT+EXER condition. Based on pilot data, a) 66% reduction in the number of people who meet DSM-IV criteria for MDD is expected at POST compared to baseline; b) 86-90% percent of cases with MDD remission at POST are expected to remain remitted at the 6-month follow-up; c) severity of depression, as measured by the BDI-II, will significantly decrease from baseline to POST and baseline to follow-up assessments, after co-varying the effect of gender, number of T2DM complications, and exposure to treatment. It is anticipated that participants in the CBT+EXER condition will show the longest remission rates of depression followed by those in EXER and CBT.
The secondary hypotheses are:
3. Changes in CVD risk factors in the intervention groups compared to UC over time. Physical activity capacity, as measured by the 6-minute walk test (6MWT), will demonstrate the greatest improvements in the CBT+EXER arm, closely followed by the EXER arm at follow-up assessment compared to baseline. Participants in the CBT and UC arms are not expected to show significant improvements. LDL-C is expected to improve at POST in the EXER and CBT+EXER conditions consistent with pilot data.
4. Cost Effectiveness Analyses. The predicted incidence of complications, particularly coronary heart disease (CHD), will be lower among those who receive CBT+EXER condition compared to the CBT, EXER and UC conditions. Further, the costs of this intensive intervention will be offset by a decrease in complication incidence.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Talk therapy (CBT)
Participants randomized the talk therapy arm received 10 weeks of CBT or "talk therapy." The goal of CBT was to provide individuals with skills and concepts that they may use to: 1) manage and reduce depressive symptoms; 2) prevent the onset and severity of future depressive episodes; and 3) generalize these skills to diabetes management.
CBT interventionists facilitated patient management of depressive symptoms by providing participants with:
* Education about depression and the cognitive-behavioral therapy model;
* A safe relationship for participants to explore their symptom patterns and try to new tools to address them;
* Coaching as participants fully engage emotional and behavioral strategies.
Program ACTIVE CBT
Please see the Talk Therapy arm description above.
Exercise (EXER)
Participants randomized to the exercise arm were enrolled in a 12-week physical activity intervention designed to increase aerobic physical activity. Participants were asked to complete 100 minutes of aerobic activity in Week 1, 125 minutes in Week 2, and 150 minutes per week of physical activity in Weeks 3-12. In addition, participants received 6 exercise training classes in which safe exercise practices were introduced and practiced, free access to a local exercise facility, use of a pedometer, completion of activity logs each week, and received an exercise workbook that addressed social and motivational aspects of physical activity.
Program ACTIVE Exercise
Please see the Exercise arm description above.
Talk therapy + exercise (CBT+EXER)
Participants randomized to the combination therapy received both talk therapy and exercise concurrently over a 12-week period as detailed above.
Program ACTIVE
Please see the Talk Therapy + Exercise arm description above.
Usual care (UC)
Participants randomized to usual care received no study intervention.
Usual Care - No intervention
Please see the Usual Care arm description above.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Program ACTIVE Exercise
Please see the Exercise arm description above.
Program ACTIVE CBT
Please see the Talk Therapy arm description above.
Program ACTIVE
Please see the Talk Therapy + Exercise arm description above.
Usual Care - No intervention
Please see the Usual Care arm description above.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* diagnosis of type 2 diabetes for at least one year duration or longer
* major depression lasting two weeks or longer
Exclusion Criteria
* history of continuous insulin therapy since diabetes diagnosis
* stage 2 hypertension as defined by JNC VII
* recent cardiac events (e.g., unstable angina, diagnosed angina, PTCA, any cardiac intervention for CAD or tachydysrhythmias in the past six months)
* laser surgery for proliferative retinopathy in the past six months
* history of stroke, lower limb amputation, asensory peripheral neuropathy, aortic stenosis or other sever valvular heart disease, atrial fibrillation, severe COPD (e.g., basal oxygen), class III or IV heart failure
* active suicidal ideation or history of suicide attempt
* history of bipolar disorder
* history of psychotic disorder
* current substance abuse or dependence disorder
* individuals who report the use of a current antidepressant medication for five weeks or less were excluded or deferred for later screening after the 6 week period
* individual who were receiving psychotherapy from a mental health provider for depression were excluded
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NIH
West Virginia University
OTHER
Ohio University
OTHER
University of Michigan
OTHER
Indiana University
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Mary de Groot
Associate Professor
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Indiana University
Indianapolis, Indiana, United States
Ohio University
Athens, Ohio, United States
West Virginia University
Morgantown, West Virginia, United States
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
de Groot M, Shubrook J, Schwartz F, Hornsby WG Jr, Pillay Y, Saha C. Program ACTIVE II: Design and Methods for a Multi-Center Community-Based Depression Treatment for Rural and Urban Adults with Type 2 Diabetes. J Diabetes Res Ther. 2015 Aug;1(2):10.16966/2380-5544.108. doi: 10.16966/2380-5544.108. Epub 2015 Aug 5.
de Groot M, Crick KA, Long M, Saha C, Shubrook JH. Lifetime Duration of Depressive Disorders in Patients With Type 2 Diabetes. Diabetes Care. 2016 Dec;39(12):2174-2181. doi: 10.2337/dc16-1145. Epub 2016 Oct 11.
de Groot M, Shubrook JH, Hornsby WG Jr, Pillay Y, Mather KJ, Fitzpatrick K, Yang Z, Saha C. Program ACTIVE II: Outcomes From a Randomized, Multistate Community-Based Depression Treatment for Rural and Urban Adults With Type 2 Diabetes. Diabetes Care. 2019 Jul;42(7):1185-1193. doi: 10.2337/dc18-2400. Epub 2019 May 21.
Kuo S, Ye W, de Groot M, Saha C, Shubrook JH, Hornsby WG Jr, Pillay Y, Mather KJ, Herman WH. Cost-effectiveness of Community-Based Depression Interventions for Rural and Urban Adults With Type 2 Diabetes: Projections From Program ACTIVE (Adults Coming Together to Increase Vital Exercise) II. Diabetes Care. 2021 Apr;44(4):874-882. doi: 10.2337/dc20-1639. Epub 2021 Feb 19.
Myers BA, Pillay Y, Guyton Hornsby W Jr, Shubrook J, Saha C, Mather KJ, Fitzpatrick K, de Groot M. Recruitment effort and costs from a multi-center randomized controlled trial for treating depression in type 2 diabetes. Trials. 2019 Nov 6;20(1):621. doi: 10.1186/s13063-019-3712-x.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
1308973934
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.